Evidence Table D-35. Delirium free days outcomes for studies comparing interventions to treat delirium

| Author, year | Population | Intervention group, n | Control group, n | Route of administration | Outcome definition | Median (IQR) days, intervention group | Median (IQR), days, control group | Measure of association (95% CI) |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| First-generation antipsychotic vs. placebo |  |  |  |  |  |  |  |  |
| Girard, 2010[4](#_ENREF_4) | > 18 years MV medical and surgical ICU patients | Haloperidol (Planned dose: 5 Median dose: 15 (10.8-17), 35 | Placebo (Planned dose: 5ml), 36 | Oral | delirium/coma-free days during the 21-day study period. | 14 (6 to 18) | 12.5 (1.2 to 17.2) |   |
| Girard, 2018[29](#_ENREF_29) | Patients over 18 years of age in the medical or surgical ICU, with delirium | Haloperidol (Mean dose: 11mg Dose range: 2.5-20mg), 192 | Placebo (Mean dose: Not reported), 184 | Intravenous | Days alive without delirium or coma | 8 (0 to 11) | 7 (0 to 11) | OR 0.88 (95% CI: 0.64 to 1.21), p=0.26 |
| Girard, 2018[29](#_ENREF_29) | Patients over 18 years of age in the medical or surgical ICU, with delirium | Haloperidol (Mean dose: 11mg Dose range: 2.5-20mg), 192 | Placebo (Mean dose: Not reported), 184 | Intravenous | Days alive without delirium or coma | Adjusted median: 7.9 (95% CI: 4.4 to 9.6) | Adjusted median: 8.5 (95% CI: 5.6 to 9.9) | OR 0.88 (95% CI: 0.64 to 1.21), p=0.26 |
| Page, 2013[10](#_ENREF_10), [27](#_ENREF_27) | ICU patients needing MV within 72 hours of admission were enrolled | Haloperidol (Planned dose: 2.5mg), 71 | Placebo (Planned dose: 0.5ml), 70 | Intravenous | Alive, delirium free, and coma free days in first 14 days, median (IQR) | 5 (0 to 10) | 6 (0 to 11) | Mean difference -0.48 (95% CI: -2.08 to 1.21), p=0.53 |
| Page, 2013[10](#_ENREF_10), [27](#_ENREF_27) | ICU patients needing MV within 72 hours of admission were enrolled | Haloperidol (Planned dose: 2.5mg), 71 | Placebo (Planned dose: 0.5ml), 70 | Intravenous | Alive, delirium free, and coma free days in first 28 days | 19 (0 to 24) | 19.5 (0 to 25) | Mean difference -0.26 (95% CI: -3.72 to 3.46), p=0.57 |
| Second-generation antipsychotic vs. placebo |  |  |  |  |  |  |  |  |
| Girard, 2010[4](#_ENREF_4) | > 18 years MV medical and surgical ICU patients | Ziprasidone (Planned dose: 40 Median dose: 113 (81-140), 30 | Placebo (Planned dose: 5ml), 36 | Oral | Delirium/coma-free days during the 21-day study period. | 15 (9.1 to 18) | 12.5 (1.2 to 17.2) |   |
| Girard, 2018[29](#_ENREF_29) | Patients over 18 years of age in the medical or surgical ICU, with delirium | Ziprasidone (Mean dose: 20mg Dose range: 5.0-40mg), 190 | Placebo (Mean dose: Not reported), 184 | Intravenous | Days alive without delirium or coma | 8 (2 to 11) | 7 (0 to 11) | OR 1.04 (95% CI: 0.73-1.48), p=0.26 |
| Girard, 2018[29](#_ENREF_29) | Patients over 18 years of age in the medical or surgical ICU, with delirium | Ziprasidone (Mean dose: 20mg Dose range: 5.0-40mg), 190 | Placebo (Mean dose: Not reported), 184 | Intravenous | Days alive without delirium or coma | Adjusted median: 8.7 (95% CI: 5.9 to 10) | Adjusted median: 8.5 (95% CI: 5.6 to 9.9) | OR 1.04 (95% CI: 0.73-1.48), p=0.26 |

| Author, year | Population | Intervention group, n | Control group, n | Route of administration | Outcome definition | Median (IQR) days, intervention group | Median (IQR), days, control group | Measure of association (95% CI) |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| First-generation antipsychotic vs. second-generation antipsychotic |  |  |  |  |  |  |  |  |
| Girard, 2010[4](#_ENREF_4) | > 18 years MV medical and surgical ICU patients | Ziprasidone (Planned dose: 40 Median dose: 113 (81-140), 30 | Haloperidol (Planned dose: 5 Median dose: 15 (10.8-17), 35 | Oral | Delirium/coma-free days during the 21-day study period. | 15 (9.1 to 18) | 14 (6 to 18) |   |
| Girard, 2018[29](#_ENREF_29) | Patients over 18 years of age in the medical or surgical ICU, with delirium | Ziprasidone (Mean dose: 20mg Dose range: 5.0-40mg), 190 | Haloperidol (Mean dose: 11mg Dose range: 2.5-20mg), 192 | Intravenous | Days alive without delirium or coma | 8 (2 to 11) | 8 (0 to 11) |   |
| Girard, 2018[29](#_ENREF_29) | Patients over 18 years of age in the medical or surgical ICU, with delirium | Ziprasidone (Mean dose: 20mg Dose range: 5.0-40mg), 190 | Haloperidol (Mean dose: 11mg Dose range: 2.5-20mg), 192 | Intravenous | Days alive without delirium or coma | Adjusted median: 8.7 (95% CI: 5.9 to 10) | Adjusted median: 7.9 (95% CI: 4.4 to 9.6) |   |

CI=confidence interval; ICU=intensive care unit; IQR=interquartile range; MV=mechanical ventilation